FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a complex of sitagliptin tannate, in which the ratio of sitagliptin to tannic acid is approximately 1:2 by weight. Invention also refers to a pharmaceutical composition and to an oral dosage form.
EFFECT: technical result is obtaining sitagliptin tantalum complex with a pleasant taste and having a low release rate at neutral pH and immediate release at acidic pH, that enables to create an oral dosage form with a pleasant taste, which is easier to swallow, which improves patient compliance with the therapeutic regimen when taking the drug.
7 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATION COMPRISING IBAT-INHIBITOR AND BILE ACID BINDER | 2011 |
|
RU2619215C2 |
| COMBINED THERAPY WITH GPR119 AGONISTS AND DPP-4 INHIBITORS | 2020 |
|
RU2818562C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING AMINO COMPOUND | 2012 |
|
RU2607480C2 |
| IBAT INHIBITOR FOR TREATING HEPATIC DISORDERS | 2011 |
|
RU2591188C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DIABETES AND RELATED METABOLIC DISEASES | 2021 |
|
RU2809286C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATHOEPATITIS | 2021 |
|
RU2803733C1 |
| AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR TREATING OR PREVENTING DIABETES | 2010 |
|
RU2550508C2 |
| COMPOSITIONS OF METFORMIN WITH REDUCED WEIGHT | 2010 |
|
RU2564901C2 |
| COMBINATION FOR REGENERATIVE THERAPY OF TYPE 1 DIABETES MELLITUS | 2018 |
|
RU2694527C1 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
